.
MergerLinks Header Logo

Announced

Completed

Viking Global Investors led a $120m Series B financing round for Affinivax.

Financials

Edit Data
Transaction Value£97m
Consideration TypeCash
Capital Owned-
Capital Bid For-
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

United States

healthcare industry

Private Equity

Biotechnology

Friendly

Acquisition

Completed

biotechnology company

biotechnology products

Minority

Single Bidder

Private

Venture Capital

Domestic

Synopsis

Edit

Asset management firm Viking Global Investors led a $120m Series B financing round for Affinivax, a clinical-stage biotechnology company. The round saw participation also from private equity firms Bain Capital Life Sciences and Ziff Capital Partners. “We are very pleased to welcome such a strong syndicate of new investors to Affinivax and look forward to benefiting from their deep experience. Having built the company to over 70 employees and advanced MAPS into clinical testing in less than 5 years, we are very excited to look ahead to our next phase of growth, taking our lead pneumococcal vaccine through Phase 3 testing and bringing several additional novel MAPS vaccines and immunotherapies into clinical trials," Steven B. Brugger, Affinivax CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US